Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth

Esperion Therapeutics Inc (NASDAQ:ESPR) Surpasses Revenue Estimates, Narrows Losses in Q2 2025

Esperion Therapeutics Inc (NASDAQ:ESPR) reported its second-quarter 2025 financial results, delivering revenue growth that exceeded analyst expectations while narrowing its losses. The market reacted positively, with shares rising more than 12% in pre-market trading following the announcement.

Key Financial Highlights

• Revenue Beat: The company reported total revenue of $82.4 million, a 12% year-over-year increase and significantly above the consensus estimate of $65.05 million.
• U.S. Net Product Revenue Growth: Sales in the U.S. surged 42% year-over-year to $40.3 million, reflecting strong demand for its cholesterol-lowering therapies, including NEXLETOL and NEXLIZET.
• Improved Earnings Per Share (EPS): The company posted an EPS of -$0.02, a notable improvement compared to the estimated -$(0.13). This suggests better-than-expected cost management and operational efficiency.
• Prescription Growth: Total retail prescription equivalents increased 10% from the previous quarter, indicating continued adoption of its therapies.

Market Reaction

The strong revenue performance and reduced losses appear to have reassured investors, leading to a sharp pre-market rally. The stock had been relatively flat over the past week (-0.06%) but gained nearly 30% over the past two weeks and 34% over the past month, suggesting growing optimism ahead of the earnings release.

Outlook vs. Analyst Estimates

While the press release did not provide explicit forward guidance, analysts currently project:

• Q3 2025 Revenue: $81.28 million (vs. Q2’s $82.4 million)
• Q3 2025 EPS: $0.023 (a potential return to profitability)
• Full-Year 2025 Revenue: $352.59 million
• Full-Year 2025 EPS: -$(0.19)

If Esperion maintains its current growth trajectory, particularly in U.S. product sales, it may continue to outperform expectations.

Press Release Summary

The earnings report emphasized:

• Strong revenue growth, particularly in U.S. product sales.
• Increased prescription volume, suggesting market penetration for its LDL-C therapies.
• Progress in narrowing losses, a positive sign for long-term profitability.

For a deeper dive into Esperion’s earnings and future estimates, see the full earnings and estimates breakdown here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.